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Part 1.  Experimental details and characterization of S-diastereomers and racemic 
mixtures. 
 
S-(-)-2-bromopropan-1-ol (7b).  The same procedure was used as described for 7a 
beginning with 3.0 mL (5.09 g, 0.033 mol) of S-(-)-2-bromopropionic acid.  Yield: 72%   
1H NMR (400 MHz, CDCl3) δ 1.62 (d, 3H, CH3CHBrCH2OH, J = 8), 2.14-2.24 (s, 1H, 
CH3CHBrCH2OH), 3.60-3.82 (m, 2H, CH3CHBrCH2OH), 4.20-4.36 (m, 1H, 
CH3CHBrCH2OH).  13C NMR (100 MHz, CDCl3) δ 22.1, 53.74, 68.90. 
 
2-bromopropan-1-ol (7c).  The same procedure was used as described for 7a beginning 
with 10.0 ml (16.96 g, 0.111 mol) of 2-bromopropionic acid.  Yield: 66%.  1H NMR (400 
MHz, CDCl3) δ 1.52-1.62 (d, 3H, CH3CHBrCH2OH, J = 8), 3.1 (s, 1H, 
CH3CHBrCH2OH), 3.54-3.70 (m, 2H, CH3CHBrCH2OH), 4.02-4.15 (m, 1H, 
CH3CHBrCH2OH).  13C NMR (100 MHz, CDCl3) δ 21.23, 52.73, 67.42. 
 
S-(-)-2-bromopropan-1-β-D-galactose tetraacetate (8b).  The S-diastereomer was 
synthesized by the same procedure described for 8a beginning with 0.2820 g (0.0020 
mol) 7b in a 74.4% yield.  1H NMR (500 MHz, CDCl3) δ 1.66-1.67 (d, 3H, methyl, J = 
6.5), 1.99-2.16 (m, 12H, OAc), 3.65-3.69 (m, 2H, CH3CHBrCH2O-sugar), 3.90-3.93 (m, 
1H, CH3CHBrCH2O-sugar), 4.00-4.03 (m, 2H, H-6), 4.11-4.20 (m, 1H, H-4), 4.53-4.55 
(m, 1H, H-5), 5.02-5.05 (m, 1H, H-3), 5.22-5.26 (m, 2H, H-2), 5.40-5.40 (m, 1H, H-1).  
13C NMR (125 MHz) δ 20.87, 20.95, 21.14, 22.69, 46.15, 61.44, 67.14, 68.80, 70.91, 
70.97, 75.14, 101.91, 170.28, 170.36, 170.54.  ESI-MS m/z = 492.8 (M + Na+). 
 
2-bromopropan-1-β-D-galactose tetraacetate (8c).   The racemic mixture of 8 was 
synthesized by the same procedure as for 8a beginning with 6.46 g (0.046 mol) 7c in a 
yield of 70%.  1H NMR (400 MHz) δ 1.62-1.76 (d, 3H, methyl, J = 6.5), 1.88-2.18 (m, 
12H, OAc), 3.60-3.68 (m, 2H, CH3CHBrCH2O-sugar), 3.86-3.92 (m, 1H, 
CH3CHBrCH2O-sugar), 4.16-4.22 (m, 3H, H-5 and H-6), 4.52-4.58 (m, 1H, H-4), 5.0-
5.18 (m, 1H, H-2), 5.20-5.28 (m, 1H, H-3), 5.39 (m, 1H, H-1).  13C NMR (100 MHz) δ 
20.49, 20.57, 20.78, 20.94, 22.19, 22.37, 45.95, 46.34, 60.27, 61.19, 66.96, 68.53, 68.60, 
70.67, 74.84, 75.07, 101.31, 101.60, 169.36, 169.99, 170.14, 170.26.  ESI-MS m/z = 
492.8 (M+Na+). 
 
S-(-)-(2-(1,4,7,10-tetraazacyclododecyl)propan)-1-β-D-galactose tetraacetate (9b).  
Synthesized 9b according to the procedure for 9a beginning with 1.8441 g (0.00393 mol) 
of 8a.   1H NMR (400 MHz, CD3CN) δ 0.78-0.84 (d, 3H, methyl, J = 6.0), 1.85-2.22 (m, 
12H, OAc), 2.74-3.35(br, 16H, cyclen), 3.92-4.08 (m, 2H, methylene on linker), 4.16-4.2 
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(m, 1H, methine on linker), 4.38-4.42 (m, 3H, H-5 and H-6), 4.72 (m, d, 1H, H-4), 4.98-
5.08 (m, 1H, H-2), 5.10-5.18 (m, 1H, H-3), 5.40 (m 1H, H-1).   13C NMR (125 MHz, 
CD3CN) δ 7.92, 20.15, 20.30, 20.37, 20.40, 53.41, 61.52, 67.47, 68.76, 70.56, 72.04, 
73.49. 104.5, 170.02, 170.75, 170.79, 171.28. ESI-MS m/z = 561.3 (M + H+). 
 
(2-(1,4,7,10-tetraazacyclododecyl)propan)-1-β-D-galactose tetraacetate (9c):  
Compound 9c was synthesized using the procedure described for 9a.  1H NMR (400 
MHz, CDCl3) δ 0.82-0.98 (d, 3H, methyl, J = 6.0), 1.95-2.18(m, 12H, OAc), 2.8-3.42 (br, 
16H, cyclen), 3.80-4.1 (m, 3H, methylene and methine on linker), 4.18-4.22 (m, 2H, H-
6), 4.48 (d, 1H, H-4), 4.96-4.98 (m, 1H, H-5), 5.0-5.06 (m, 1H, H-3), 5.40 (m, 2H, H-2 
and H-1).  13C NMR (125 MHz, CD3CN) δ 7.85, 8.20, 20.09, 20.21, 20.34, 53.11, 53.43, 
61.29, 61.52, 67.47, 67.66, 68.77, 69.09, 70.31, 70.56, 70.89, 71.55, 72.07, 101.5, 104.5, 
170.02, 170.26, 170.55, 171.27, 171.49.   ESI-MS m/z = 561.2 (M + H+). 
 
 (S)-(-)-(2-(4,7,10-trismethylcarboxymethyl-(1,4,7,10-tetraazacyclododecyl))propan)-
1-β-D-galactose tetraacetate (10b).  The S-diastereomer 10b, was synthesized 
according to the procedure for 10a beginning with 1.1828 g of 9b.  The yield was 
calculated over last two reactions beginning with 8a: 25%.  1H NMR (500 MHz, CD3CN) 
δ 1.3 (d, 3H, methyl, J = 6), 1.98-2.2 (m, 12H, OAc), 2.3-3.6 (m, 16H, cyclen), 3.8-3.98 
(m, 9H, -OCH3), 4.0-4.15 (m, 5H, methylene and methine on linker and H-6), 4.55-4.80 
(br, 3H, H-5, H-4, and H-3), 5.1 (s, 1H, H-2), 5.4 (s, 1H, H-1).  13C NMR (CD3CN, 125 
MHz) δ 20.72, 20.76, 20.90, 54.40, 60.33, 67.32, 68.72, 70.25, 71.43, 71.54, 101.24, 
169.46, 169.93, 170.75, 171.48.  ESI-MS: m/z = 777.6 (M + H+), 799.5 (M + Na+). 
 
(2-(4,7,10-trismethylcarboxymethyl-(1,4,7,10-tetraazacyclododecyl))propan)-1-β-D-
galactose tetraacetate (10c).  The racemic mixture was synthesized according to 
procedure described for 10a beginning with 1.0148 g of 9c.  Yield was calculated over 
the last two reactions beginning with 8c: 37%.  1H NMR (500 MHz, CD3CN) δ 1.2-1.3 
(d, 3H, methyl, J = 6.0), 1.9-2.2 (m, 12H, OAc), 2.4-3.6 (br, 16H, cyclen), 3.65-3.8 (m, 
9H, -OCH3), 3.9-4.2 (br, methylene and methine on linker and H-6), 4.6 (m, 1H, H-4), 
4.7 (m, 1H, H-5), 5.0-5.2 (m, 1H, H-3), 5.4 (m, 1H, H-2), 5.5 (s, 1H, H-1).  13C NMR 
(125 MHz, CD3CN) δ 20.05, 20.10, 20.20, 20.35, 20.38, 51.17, 51.41, 51.46, 52.18, 
52.28, 52.38, 52.52, 55.12, 55.57, 55.67, 61.49, 61.55, 67.55, 67.62, 68.95, 69.06, 69.14, 
70.68, 70.80, 70.96, 71.13, 100.48, 101.24, 170.05, 170.48, 171.30, 171.51, 171.57, 
174.33, 174.76, 175.15.   ESI-MS: m/z = 777.2 (M + H+), 799.2 (M + Na+). 
 
Kinetic resolution of S-(-)-propylene oxide (11b).  Propylene oxide was kinetically 
resolved as described above beginning with 5 mL (4.15 g, 0.071 mol) of propylene oxide 
and 0.008 eq. of  (S,S)-(+)-N,N’-bis (3,5-di-tertbutylsalicylidene)-1,2-cyclohexane 
diaminocobalt(II).  (S)-propylene oxide was obtained after distillation in 23% yield 
(vapor temperature = 33 oC).  1H NMR (500 MHz, CDCl3) δ 1.26-1.34 (d, 3H, methyl, J 
= 5), 2.42-2.46 (m, 1H, methylene), 2.74-2.78 (m, 1H, methylene), 2.96-3.00 (m, 1H, 
methine).  13C NMR (125 MHz, CDCl3) δ 18.12, 48.16, 48.39. 
 
S-(-)-1-bromopropan-2-ol (12b).  The S-diastereomer was synthesized using the 
procedure described for 12a beginning with 8 mL (6.63 g, 0.11 mol) of 11b.  Yield: 57%.  
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1H NMR (500 MHz, CDCl3) δ 1.28-1.36 (d, 3H, methyl, J = 6.0), 1.88 (br, 1H, -OH), 
3.34-3.40 (m, 1H, methylene), 3.48-3.04 (m, 1H, methylene), 3.96-4.02 (m, 1H, 
methine).  13C NMR (125 MHz, CDCl3) δ 21.22, 41.50, 68.11. 
 
1-bromopropan-2-ol (12c).  The racemic mixture of 12 was synthesized according to the 
procedure described for 12a beginning with 10 mL (8.29 g, 0.14 mol)  of 11c.  Yield: 
76%.  1H NMR (500 MHz, CDCl3) δ 1.25-1.32 (d, 3H, methyl, J = 6.0), 1.85 (br, 1H, -
OH), 3.32-3.38 (m, 1H, methylene), 3.45-3.51 (m, 1H, methylene), 3.94-4.02 (m, 1H, 
methine).  13C NMR (125 MHz, CDCl3) δ 21.23, 41.51, 68.11.   
S-(-)-1-bromopropan-2-β-D-galactose tetraacetate (13b).  The S-diastereomer was 
synthesized using the procedure described for 13a beginning with 4.3867 g (0.0315 mol) 
of 12b and 10.1832 g (0.026 mol) of β-D-galactosepentaacetate.  Single crystals of 
compound 13b were obtained from a solution of ether/pet. ether, methanol, and ethyl 
acetate.  Yield: 70%.  1H NMR (500 MHz, CDCl3) δ 1.30-1.38 (d, 3H, methyl, J = 6.5), 
1.98-2.40 (m, 12H, OAc), 3.28-3.36 (m, 2H, -CH2Br), 3.86-3.98 (m, 2H, methine on 
linker and H-5), 4.05-4.20 (m, 2H, H-6), 4.55-4.64 (m, 1H, H-4), 4.96-5.02 (m, 1H, H-3), 
5.18-5.24 (m, 1H, H-2), 5.38 (m, 1H, H-1).  13C NMR (125 MHz, CDCl3) δ 20.85, 20.94, 
21.01, 21.28, 36.23, 61.18, 67.13, 68.86, 70.79, 70.98, 76.98, 101.67, 168.57, 176.13, 
170.27, 170.37.  ESI-MS: m/z = 493.0 (M + Na+), 509.2 (M + K+). 
1-bromo-propan-2-β-D-galactose tetraacetate (13c).  The racemic mixture was 
synthesized using the procedure described for 13a beginning with 5.2619 g (0.038 mol) 
of 12c and 12.2332 g (0.031 mol) of β-D-galactosepentaacetate.  Yield: 45%.  1H NMR 
(500 MHz, CDCl3) δ 1.33-1.38 (d, 3H, methyl, J = 6.5), 1.92-2.20 (m, 12H, OAc), 3.32-
3.40 (m, 1H, -CH2Br), 3.42-3.48 (m, 1H, -CH2Br), 3.88-3.98 (m, 2H, methine on linker 
and H-5), 4.12-4.20 (m, 2H, H-6), 4.50-4.58 (m, 1H, H-4), 4.98-5.10 (m, 1H, H-3), 5.28-
5.40 (m, 2H, H-1 and H-2).  13C NMR (125 MHz, CDCl3) δ 18.92, 20.55, 20.89, 20.92, 
20.98, 36.18, 36.52, 61.54, 62.09, 62.14, 66.77, 67.17, 67.66, 67.71, 68.22, 68.30, 68.39, 
68.47, 70.87, 71.03, 75.00, 75.37, 95.25, 96.70, 170.46, 170.67, 170.69, 170.88.  ESI-
MS: m/z = 493.1 (M + Na+), 509.1 (M + K+).   
 
S-(-)-1-(1,4,7,10-tetraazacyclododecyl)propan-2-β-D-galactose tetraacetate (14b).  
The S-diastereomer was synthesized using the method described for 14a beginning with 
3.1863 g (0.0068 mol) of 13b.  1H NMR (500 MHz, CDCl3) δ 1.08-1.18 (d, 3H, methyl, J 
= 6.5), 1.95-2.28 (m, 12H, OAc), 2.70 (s, 2H, methylene on linker), 2.90-3.50 (br, 16H, 
cyclen), 3.90-4.02 (m, 1H, methine on linker), 4.16-4.24 (m, 1H, H-5), 4.25-4.36 (m, 2H, 
H-6), 4.62-4.68 (m, 1H, H-4), 4.90-4.98 (m, 1H, H-3), 5.02-5.12 (m, 1H, H-2), 5.42 (m, 
1H, H-1).  ESI-MS: m/z = 561.2 (M + H+). 
 
  1-(1,4,7,10-tetraazacyclododecyl)propan-2-β-D-galactose tetraacetate (14c).  The 
racemic mixture was synthesized according to the method described for 14a beginning 
with 3.5534 g (0.0076 mol) of 13c.  1H NMR (500 MHz, CDCl3) δ  1.08-1.16 (d, 3H, 
methyl, J = 6.5), 1.95-2.30 (m, 12H, OAc), 2.70 (s, 2H, methylene on linker), 2.92-3.52 
(br, 16H, cyclen), 3.90-4.02 (m, 1H, methine on linker), 4.18-4.28 (m, 1H, H-5), 4.25-
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4.36 (m, 2H, H-6), 4.62-4.68 (m, 1H, H-4), 4.90-4.98 (m, 1H, H-3), 5.02-5.12 (m, 1H, H-
2), 5.42 (m, 1H, H-1).  ESI-MS: m/z = 561.2 (M + H+). 
 
S-(-)-1-(4,7,10-trismethylcarboxymethyl-(1,4,7,10-tetraazacyclododecyl))propan-2-
β-D-galactose tetraacetate (15b).  The S-diastereomer was synthesized using the 
procedure described for 15a beginning with 1.6147 g (0.0029 mol) of 14b.  The yield 
over last two reactions starting from 13b: 39%.  1H NMR (500 MHz, CDCl3) δ 1.18-1.19 
(d, 3H, methyl, J = 6.5 ), 1.89-2.09 (m, 12H, acetates), 2.73-3.42 (m, 16H, cyclen), 3.64-
3.74 (m, 9H, -OCH3), 3.90-4.15 (br, methylene and methine on linker and H-6), 4.55-
4.62 (m, 1H, H-4), 4.91-5.00 (m, 2H, H-3 and H-5), 5.07-5.15 (m, 1H, H-2), 5.32 (s, 1H, 
H-1).  13C NMR (125 MHz, CDCl3) δ 20.39, 20.74, 20.89, 21.41, 48.31, 50.69, 51.96, 
52.09, 52.89, 52.96, 55.69, 55.99, 55.87, 61.56, 67.26, 67.38, 69.31, 69.42, 70.87, 70.94, 
71.41, 73.25, 95.01, 100.98, 169.66, 169.96, 170.08, 170.17, 170.42, 170.62, 171.40, 
171.82, 174. 20.  ESI-MS: m/z = 777.2 (M + H+), 799.3 (M + Na+).   
 
1-(4,7,10-trismethylcarboxymethyl-(1,4,7,10-tetraazacyclododecyl))propan-2-β-D-
galactose tetraacetate (15c).  The racemic mixture was synthesized using the method 
described for 15a beginning with 1.6173 g (0.0029 mol) of 14c.  Yield over last two 
reactions starting with 13c: 51%.  1H NMR (500 MHz, CDCl3) δ 1.17-1.18 (d, 3H, 
methyl, J = 6.5), 1.89-2.09 (m, 12H, acetates), 2.65-3.60 (m, 16H, cyclen), 3.64-3.75 (m, 
9H, -OCH3), 3.92-3.98 (br, methylene and methine on linker and H-6),  4.99-5.36 (m, 4H, 
H-3, H-5, H-2, H-1).  13C NMR (125 MHz, CDCl3) δ 20.93, 48.24, 50.99, 52.13, 52.73, 
52.98, 55.87, 56.16, 61.59, 66.86, 67.51, 67.94, 70.63, 94.51, 95.01, 170.39, 170.54, 
170.72, 171.24, 171.41, 171.59, 174.27, 174.92.  ESI-MS: m/z = 777.2 (M + H+), 799.3 
(M + Na+).   
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